Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from its Phase I/IIa clinical studies with their RH5.1 bloodstage malaria vaccine at a scientific meeting in New Orleans.
The vaccine, developed and manufactured using ExpreS2ion’s ExpreS2 platform, was shown to be safe and it is the first vaccine to demonstrate a reduction in the parasite multiplication rate following a blood-stage controlled human malaria infection. In the results it is concluded, that RH5.1 is safe, immunogenic, and has a moderate, but significant, impact on parasite multiplication rate following primary and secondary controlled human malaria infection (CHMI) with blood-stage P. falciparum.
Furthermore, the delayed fractional dosing arm of the study shows highly promising improved immunogenicity leading to a stronger, longer-lasting, and improved avidity antibody response. The AS01B adjuvant used in this study was supplied by the global pharmaceutical company GlaxoSmithKline.
“The promising results from this clinical study are a great achievement from the University of Oxford group and an important step towards creating a malaria vaccine for a broader large-scale use. We are excited to be a collaboration partner and delighted that our ExpreS2 platform is used for the development and production of their cutting-edge RH5.1 malaria vaccine,” says ExpreS2ion’s CEO Dr. Steen Klysner.
In addition to the RH5.1 clinical program, ExpreS2ion’s patented ExpreS2 platform is currently being used in several other malaria vaccine projects, of which one is also a collaboration with University of Oxford. ExpreS2 is also utilised in a number of projects elsewhere for the development of vaccines for major health threats such as Ebola and breast cancer. The breast cancer project is developed by the company’s joint venture AdaptVac.
Photo: ExpreS2ion
